Sanofi Pasteur R&D Portfolio

14 vaccines in development(1)

Phase I
Phase II
Phase III
Submitted

Rotavirus
Live Attenuated Tetravalent
Rotavirus oral vaccine

Streptococcus pneumonia
Meningitis & pneumonia vaccine

Pseudomonas aeruginosa
Antibody fragment product
Prevention of ventilator-
associated pneumonia

Tuberculosis
Recombinant subunit vaccine

ACAM-Cdiff
Clostridium difficile Toxoid vaccine

Rabies VRVg
Purified vero rabies vaccine

Meninge ACYW conj.
2nd generation meningococcal
conjugate infant vaccine

DTP-HepB-Polio-Hib
Pediatric hexavalent vaccine

Quadracel®
Diphtheria, tetanus, pertussis and polio vaccine
4-6 years of age

Dengue
Mild-to-severe
dengue fever vaccine

Vaxigrip® QIV IM
Quandrivalent inactivated influenza vaccine

Fluzone® QIV ID
Quadrivalent inactivated
influenza vaccine intradermal

 

Hexaxim™ / New hexavalent vaccine
DTP-HepB-Polio-Hib vaccine

Fluzone® QIV IM
Quadrivalent inactivated
influenza vaccine

 

(1) As of February 7, 2013, from phase I to “submitted”